Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors

Anticancer Research

Volumn 30, Issue 1, 2010, Pages 167-174

  Luu, Thehang ^a   Chow, Warren ^a   Lim, Dean ^a   Koczywas, Marianna ^a   Frankel, Paul ^b   Cristea, Mihaela ^a   Margolin, Kim ^a   Doroshow, James H ^c   Somlo, George ^a   Gaur, Shikha ^a   Yen, Yun ^a   Morgan, Robert J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b City of Hope Comprehensive Cancer ^*  (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bortezomib; Fixed dose rate gemcitabine; Phase I; Solid tumors

Indexed keywords

BORTEZOMIB; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; AUTONOMIC NEUROPATHY; CANCER GRADING; CANCER INHIBITION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; DYSPNEA; EDEMA; ESOPHAGITIS; FATIGUE; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERNATREMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INSOMNIA; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE; LIVER FUNCTION TEST; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; STOMATITIS; SYNCOPE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HUMANS; MIDDLE AGED; NEOPLASMS; PYRAZINES;

EID: 77649241460     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Bortezomib (Bortezomib) [package insert]. Cambridge MMP, Inc., 2003.
2. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB and Plunkett W: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38: 567-572, 1990.
3. Heinemann V, Schulz L, Issels RD and Plunkett W: Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 22: 11-18, 1995.
4. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991.
5. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R and Gandhi V: Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22: 3-10, 1995.
6. Hochster HS: Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents. Int J Radiat Oncol Biol Phys 56: 24-30, 2003.
7. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P and Plunkett W: Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10: 406-413, 1992.
8. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W and Benjamin RS: Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19: 3483-3489, 2001.
9. Brand R, Capadano M and Tempero M: A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15: 331-341, 1997.
10. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R and Abbruzzese J: Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21: 3402-3408, 2003.
11. Pink MM, Pien CS, Worland P, Adams J and Kauffman MG: PS-341 enhances chemotherapeutic effect in human xenograft models. Proc Am Assoc Cancer Res 43: Abstract 787, 2002.
12. Keshelava N, Frgala T, Krejsa J, Kalous O and Reynolds CP: DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med 110: 139-153, 2005.
13. Malich G, Markovic B and Winder C: The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology 124: 179-192, 1997.
14. CTEP: Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, March 31, 2003 (http://ctep.cancer.gov), Publish Date: August 9, 2006.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
16. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S and Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999.
17. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J and Baldwin AS Jr: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61: 3535-3540, 2001.
18. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC and Anderson KC: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62: 4996-5000, 2002.
19. Teicher BA, Ara G, Herbst R, Palombella VJ and Adams J: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5: 2638-2645, 1999.
20. Papandreou C, Daliani D, Millikan RE, Tu S, Pagliaro L, Adams J, Elliott P, Nix D, Dieringer P, Thall P, Logothetis CJ, U.T.-M.D. Anderson Cancer Center H, TX; U.T.-M.D. Anderson Cancer Center H, TX; and Millennium Pharmaceuticals I, Cambridge, MA: Phase I Study of Intravenous (I.V.) Proteasome Inhibitor PS-341 in Patients (Pts) with Advanced Malignancies. Proc Am Soc Clin Oncol 20, 2001.
21. McConkey D, Pettaway C, Elliott P, Adams J, Papandreou C and Herrmann J: The proteasome as a new drug target in metastatic prostate cancer, 7th Annual Genitourinary Oncology Conference Abstract. University of Texas M.D. Anderson Cancer Center, 1999.
22. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J and Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076, 2001.
23. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J and Elliott PJ: Proteasome inhibition measurements: clinical application. Clin Chem 46: 673-683, 2000.
24. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA and Soignet SL: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20: 4420-4427, 2002.
25. Silvestris N, Cinieri S, La Torre I, Pezzella G, Numico G, Orlando L and Lorusso V: Role of gemcitabine in metastatic breast cancer patients: a short review. Breast 17: 220-226, 2008.